Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study.
PURPOSE: Despite the benefits of estrogen receptor (ER)-targeted endocrine therapies in breast cancer, many tumors develop resistance. MicroRNAs (miRNAs) have been suggested as promising biomarkers and we here evaluated whether a miRNA profile could be identified, sub-grouping ER+ breast cancer pati...
Main Authors: | Maria B Lyng, Anne-Vibeke Lænkholm, Rolf Søkilde, Karina H Gravgaard, Thomas Litman, Henrik J Ditzel |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3356496?pdf=render |
Similar Items
-
Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study.
by: Maria B Lyng, et al.
Published: (2013-01-01) -
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
by: Signe Korsgaard Skriver, et al.
Published: (2020-05-01) -
Identification of genes for normalization of real-time RT-PCR data in breast carcinomas
by: Lænkholm Anne-Vibeke, et al.
Published: (2008-01-01) -
Evaluation of Saline Sonohysterography Findings in Patients with Breast Cancer Receiving Tamoxifen Adjuvant Therapy
by: Maryam Rahmani, et al.
Published: (2016-12-01) -
The endometrium in women receiving adjuvant tamoxifen therapy after surgical treatment of breast cance
by: E V Dmitrieva, et al.
Published: (2013-12-01)